Breast Cancer Research and Treatment

, Volume 37, Issue 2, pp 179–188 | Cite as

Abnormal expression of MDM-2 in breast carcinomas

  • Carlos E. Bueso-Ramos
  • Taghi Manshouri
  • Mohammad A. Haidar
  • Yun Yang
  • Patrick McCown
  • Nelson Ordonez
  • Armand Glassman
  • Nour Sneige
  • Maher Albitar


MDM-2 is a cellular oncoprotein that binds to the p53 protein and abrogates its growth-suppressing function. At least seven MDM-2 mRNAs and five proteins (p90, p85, p76, p74, and p57) have been reported in tissue culture. MDM-2 gene amplification occurs in human sarcomas and high-grade gliomas. MDM-2 overexpression without gene amplification has been reported in leukemias and lymphomas. Here we report MDM-2 mRNA overexpression in 24 (73%) out of 33 cases of human breast carcinoma as compared with normal breast tissue. The MDM-2 overexpression was seen in the absence of MDM-2 gene amplification. MDM-2 protein expression was studied by western blot analysis in 21 of these cases of carcinoma. We found complete concordance between MDM-2 mRNA overexpression and MDM-2 protein levels. MDM-2 proteins were overexpressed in 15 of 21 breast carcinoma tissue samples but not in normal breast tissue controls. Ten of these fifteen cases overexpressed MDM-2 p57 protein, two cases overexpressed both p57 and p90, and three cases overexpressed only p90. MDM-2 overexpression was confirmed by immunohistochemistry. p53 overexpression was also studied by immunohistochemistry; 69% of breast carcinomas that overexpressed the MDM-2 mRNA had detectable nuclear p53 protein. These findings demonstrate that MDM-2 oncoprotein expression is altered in primary human breast carcinomas at both mRNA and protein levels. In addition, our results suggest that MDM-2 p57 protein represents the main MDM-2 protein altered in breast carcinomas.

Key words

gene amplification MDM-2 proteins oncoprotein p53 RT/PCR 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10: 1565–1569, 1991PubMedGoogle Scholar
  2. 2.
    Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245, 1992PubMedGoogle Scholar
  3. 3.
    Barak Y, Juven T, Haffner R, Oren M: MDM2 expression is induced by wild type p53 activity. EMBO J 2: 461–468, 1993Google Scholar
  4. 4.
    Chen J, Marechal V, Levine AJ: Mapping of the p53 and MDM2 interaction domains. Mol Cell Biol 13: 4107–4114, 1993PubMedGoogle Scholar
  5. 5.
    Wu X, Bayle JH, Olson D, Levine AJ: The p53-MDM-2 autoregulatory feedback loop. Genes Dev 7: 1126–1132, 1993PubMedGoogle Scholar
  6. 6.
    Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83, 1992PubMedGoogle Scholar
  7. 7.
    Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM-2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739, 1993PubMedGoogle Scholar
  8. 8.
    Leach FS, Tokino T, Meltzer P, Burrel M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and MDM-2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231–2234, 1993PubMedGoogle Scholar
  9. 9.
    Cordon-Cardo C, Latres E, Drobnjak M, Oliva M, Pollack D, Woodruff J, Marechal V, Chen J, Brennan M, Levine AJ: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794–799, 1994PubMedGoogle Scholar
  10. 10.
    Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CDM, Thomas M, Grimer R, Gusterson BA, Cooper CS: Abnormalities of the p53, MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69: 1052–1058, 1994PubMedGoogle Scholar
  11. 11.
    Finlay CA: The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301–306, 1993PubMedGoogle Scholar
  12. 12.
    Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82: 2617–2623, 1993PubMedGoogle Scholar
  13. 13.
    Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M: Multiple patterns of MDM-2 deregulation in human leukemias: Implications in leukemogenesis and prognosis. Leuk Lymphoma (in press)Google Scholar
  14. 14.
    Quesnel B, Preudhomme C, Oscier D, Lepelley P, O'Hooghe CM, Facon T, Zandecki M, Fenaux P: Overex-pression of the MDM-2 gene is found in some cases of haematological malignancies. Br J Haematol 88: 415–418, 1994PubMedGoogle Scholar
  15. 15.
    Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The MDM-2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84: 3158–3165, 1994PubMedGoogle Scholar
  16. 16.
    Sheikh MS, Shao ZM, Hussain A, Fontana JA: The p53-binding protein MDM-2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226–3228, 1993PubMedGoogle Scholar
  17. 17.
    Davidoff AM, Humphrey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006–5010, 1991PubMedGoogle Scholar
  18. 18.
    Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318–1327, 1993PubMedGoogle Scholar
  19. 19.
    Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Pathol 24: 469–476, 1993PubMedGoogle Scholar
  20. 20.
    Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO: p53 protein expression in mammary ductal carcinomain situ: Relationship to immunohistochemical expression of estrogen and c-erbB-2 protein. Hum Pathol 24: 463–468, 1993PubMedGoogle Scholar
  21. 21.
    Black MM, Barclay THC, Hankey BF: Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer 36: 2048–2055, 1975PubMedGoogle Scholar
  22. 22.
    Sambrook T, Fritsh E, Maniatis T: Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, Plainview, New York, 1989Google Scholar
  23. 23.
    Hsu SM, Fancer H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and the unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580, 1981PubMedGoogle Scholar
  24. 24.
    Shi SR, Key ME, Halra KL: Antigen retrieval in formalin-fixed paraffin embedded tissue: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741–748, 1991PubMedGoogle Scholar
  25. 25.
    Vojtesek B, Bártek J, Midgley CA, Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237–244, 1992PubMedGoogle Scholar
  26. 26.
    Albitar M, Peschle C, Liebhaber SA: Theta, zeta and epsilon globin mRNAs are expressed in normal adults. Blood 74: 629–637, 1989PubMedGoogle Scholar
  27. 27.
    Albitar M, Katsumata M, Liebhaber SA: Human α-globin genes demonstrate autonomous developmental regulation in transgenic mice. Mol Cell Biol 11: 3786–3794, 1991PubMedGoogle Scholar
  28. 28.
    Estes PA, Cook NE, Liebhaber SA: A difference in splicing patterns of the closely related normal and variant human growth hormone gene transcripts is determined by a minimal sequence divergence between two potential splice-acceptor sites. J Biol Chem 265: 19863–19870, 1990PubMedGoogle Scholar
  29. 29.
    Davidson NE: Biology of breast cancer and its clinical implications. Curr Opin Oncol 4: 1003–1009, 1992PubMedGoogle Scholar
  30. 30.
    Koopmans LH: An Introduction to Contemporary Statistics. PWS, Boston, MA, 1981Google Scholar
  31. 31.
    Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ: Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8: 2352–2360, 1993Google Scholar
  32. 32.
    Otto A, Deppert W: Upregulation of MDM2 expression in METH A tumor cells tolerating wild-type p53. Oncogene 8: 2591–2603, 1993PubMedGoogle Scholar
  33. 33.
    Boddy MN, Freeman PS, Borden KLB: The p53-associated protein MDM-2 contains a newly characterized zinc-binding domain called the RING finger. TIBS 19: 198–199, 1994PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Carlos E. Bueso-Ramos
    • 1
  • Taghi Manshouri
    • 1
  • Mohammad A. Haidar
    • 1
  • Yun Yang
    • 1
  • Patrick McCown
    • 1
  • Nelson Ordonez
    • 2
  • Armand Glassman
    • 1
  • Nour Sneige
    • 2
  • Maher Albitar
    • 1
  1. 1.Hematopathology Program, Department of Laboratory MedicineThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of PathologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations